A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Trial Profile

A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2016

At a glance

  • Drugs Ombitasvir (Primary) ; Paritaprevir (Primary) ; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 25 Nov 2015 Number of treatment arms changed from 4 to 6 with separate arms for genotype 1b and 2, as reported by ClinicalTrials.gov.
    • 19 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2013 Actual initiation date changed from Jan 2012 to Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top